I remember seeing a 20-40M for the market size of the Remodulin...and they projected a 75-100M revenues for 02 in the last filing.
Actelion was also approved and could be a serious competitor if the side effects do not present too many problems..
Also, the short position (20%)could create a spike if some interesting news come up....
Now, of course, we need some interesting news....:)
September looks like it will be the last terrible leg before a rally. But how sustainable will it be? I expect the housing sector to crash down very shortly.What do you think?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.